Andre the Giant's Acromegaly: What a Modern Treatment Protocol Would Look Like

Who Was Andre the Giant, Clinically Speaking?

André René Roussimoff was born in Coulommières, France in 1946. By his early teens, his hands, feet, and facial features had begun to enlarge at a rate inconsistent with normal puberty. He was never formally diagnosed in childhood, though retrospective clinical consensus points to a growth hormone (GH)-secreting pituitary adenoma that began driving excess GH production before epiphyseal plate closure, producing gigantism that transitioned into acromegaly in adulthood [1].

The Distinction Between Gigantism and Acromegaly

When GH hypersecretion begins before growth plates fuse (typically before age 15 to 17), the result is pituitary gigantism: proportional but extreme linear growth. After plate closure, the same excess GH produces acromegaly, characterized by acral enlargement (hands, feet, jaw), soft tissue swelling, and progressive organ hypertrophy [2]. Andre almost certainly experienced both phases in sequence. His linear growth accelerated in adolescence, and the coarsening of his facial features and continued hand/foot growth through his 20s and 30s are consistent with ongoing GH excess into adulthood.

Why He Was Never Treated

Multiple accounts from Andre's inner circle, including interviews with wrestler and close friend Tim White, confirm that Andre was aware of his condition but chose not to pursue surgical treatment. In the 1970s and 1980s, pituitary surgery carried higher complication rates than it does today, and effective pharmacotherapy for acromegaly did not become available until octreotide was approved by the FDA in 1988, just five years before his death [3]. It is reasonable to infer that Andre weighed the risks of the surgery available at the time against the professional consequences of a long recovery period. That calculus would look very different today.

The Clinical Burden of Untreated Acromegaly

Untreated acromegaly is not a cosmetic condition. It is a systemic endocrine disease with a standardized mortality ratio (SMR) between 1.6 and 3.2 when GH and IGF-1 levels remain elevated, according to a meta-analysis published in the Journal of Clinical Endocrinology & Metabolism [4]. The excess mortality is driven primarily by cardiovascular disease, with contributions from respiratory complications, metabolic dysfunction, and malignancy.

Cardiovascular Damage

The most clinically significant consequence for Andre was acromegalic cardiomyopathy. Chronic GH excess causes biventricular hypertrophy, myocardial fibrosis, and diastolic dysfunction that can progress to overt heart failure [5]. Andre's reported weight fluctuations (380 to over 500 lbs), combined with the hemodynamic burden of perfusing a body of that size, almost certainly accelerated this process. His death from congestive heart failure at 46 fits the expected trajectory of long-standing, untreated acromegalic heart disease.

Metabolic and Musculoskeletal Effects

GH excess induces insulin resistance. Between 20% and 56% of acromegaly patients develop impaired glucose tolerance or frank diabetes mellitus [6]. Andre was known to consume extraordinary quantities of alcohol and food. While much of this has been mythologized, the metabolic context matters: a patient with GH-driven insulin resistance who consumes high-calorie, high-carbohydrate diets faces compounding cardiovascular and metabolic risk.

Acromegalic arthropathy, caused by cartilage and periosteal overgrowth followed by joint destruction, affected Andre visibly. By the mid-1980s, his mobility was severely compromised. He required a back brace for many of his later wrestling appearances and could no longer execute the athletic maneuvers of his earlier career. Joint disease in acromegaly is often irreversible even after biochemical control is achieved [7].

Hypothesized Modern Protocol: Phase by Phase

If Andre the Giant were born in 1986 instead of 1946 and presented to an endocrinology clinic in 2026 at age 40 with the same disease profile, here is what a comprehensive treatment protocol would likely include. This is an inference-based clinical framework, not a confirmed treatment history.

Phase 1: Diagnostic Workup

The initial evaluation would include serum GH measurement (random and post-oral glucose tolerance test), serum IGF-1 (age- and sex-adjusted), and pituitary MRI with gadolinium contrast. The Endocrine Society's 2014 clinical practice guideline recommends confirming the diagnosis when IGF-1 is elevated above age-adjusted norms and GH fails to suppress below 1 ng/mL after a 75 g oral glucose load [8].

Given Andre's extreme phenotype, his tumor would almost certainly be classified as a macroadenoma (greater than or equal to 10 mm). The workup would also include an echocardiogram to assess for cardiomyopathy, fasting glucose and HbA1c for diabetes screening, colonoscopy given elevated colon polyp risk in acromegaly, and a sleep study for obstructive sleep apnea, which affects up to 70% of acromegaly patients [9].

Phase 2: Transsphenoidal Surgery

First-line treatment for acromegaly remains transsphenoidal adenomectomy, performed endoscopically by an experienced pituitary neurosurgeon. Biochemical remission rates range from 75 to 95% for microadenomas to 40 to 60% for macroadenomas, depending on tumor size, invasion of the cavernous sinus, and surgeon volume [10].

For Andre, the probability of complete surgical cure would be on the lower end. A large, likely invasive macroadenoma in a patient with decades of active disease would be expected to extend into surrounding structures. The surgical goal would shift from curative resection to maximal debulking, reducing tumor volume to improve the efficacy of subsequent medical therapy.

Recovery from modern endoscopic transsphenoidal surgery is typically 2 to 4 weeks before return to normal activity. Complication rates at high-volume centers are low: CSF leak occurs in 1 to 3% of cases, new anterior pituitary deficiency in approximately 5 to 10%, and transient diabetes insipidus in 10 to 20% [11].

Phase 3: Somatostatin Receptor Ligand Therapy

Following surgery, if GH and IGF-1 remain above target, the standard second-line treatment is a long-acting somatostatin receptor ligand (SRL). Two agents are widely used:

Octreotide LAR (Sandostatin LAR Depot): administered as an intramuscular injection every 28 days, starting at 20 mg and titrating up to 30 to 40 mg. Octreotide binds somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5), suppressing GH secretion and, in about 30% of patients, reducing tumor volume [12].

Lanreotide autogel (Somatuline Depot): a deep subcutaneous injection every 28 days at doses of 60, 90, or 120 mg. Lanreotide has a similar mechanism and efficacy profile to octreotide LAR, with IGF-1 normalization in approximately 50 to 70% of patients when used after debulking surgery [13].

For a patient with Andre's disease burden, the treating endocrinologist would likely start octreotide LAR at 20 mg monthly and titrate based on GH and IGF-1 response at 3-month intervals. Gastrointestinal side effects (diarrhea, abdominal cramping, cholelithiasis) are common initially but tend to attenuate with continued use.

Phase 4: GH Receptor Antagonist (Pegvisomant)

If SRL therapy fails to normalize IGF-1, the next step is pegvisomant (Somavert), a genetically engineered GH receptor antagonist. Pegvisomant does not suppress GH secretion or shrink the tumor; it blocks GH action at the receptor level. The key trial published in The Lancet showed IGF-1 normalization in 97% of patients at 12 months on doses up to 40 mg/day [14].

This drug would be a strong candidate for Andre's hypothesized protocol. Given decades of uncontrolled disease, his GH receptor population would be substantial, and combination SRL plus pegvisomant therapy has demonstrated superior IGF-1 normalization versus either agent alone. A 2018 study in the Journal of Clinical Endocrinology & Metabolism reported that combination therapy achieved biochemical control in 97.5% of patients who had failed SRL monotherapy [15].

Pegvisomant is administered as a daily subcutaneous injection, starting at 10 mg/day and titrating upward in 5 mg increments every 4 to 6 weeks based on IGF-1 levels. Liver function tests require monitoring every 4 to 6 weeks during the first 6 months, then every 6 months thereafter. The drug carries a low risk of hepatotoxicity (approximately 2.5% in post-marketing surveillance) [14].

Phase 5: Pasireotide as an Alternative

For patients resistant to first-generation SRLs, pasireotide LAR (Signifor LAR) is available. Pasireotide has broader somatostatin receptor binding affinity (SSTR1, 2, 3, and 5, with highest affinity for SSTR5) and demonstrated superiority over octreotide LAR in the Phase III PAOLA study, achieving biochemical control in 31.3% vs. 19.2% of patients at 12 months [16]. The tradeoff is a significantly higher rate of hyperglycemia: approximately 57% of pasireotide-treated patients developed glucose-related adverse events in PAOLA, versus 22% on octreotide LAR. In a patient like Andre, who already faced elevated metabolic risk, this side effect would require aggressive monitoring and possibly concurrent metformin or insulin therapy.

Phase 6: Radiation Therapy as Salvage

Stereotactic radiosurgery (Gamma Knife or CyberKnife) is reserved for patients with persistent disease despite surgery and medical therapy. Biochemical remission occurs in 40 to 60% of patients, but the effect is slow, with a median time to GH normalization of 3 to 10 years [17]. Radiation also carries a 20 to 50% risk of new hypopituitarism over the following decade. For Andre's hypothesized protocol, radiation would be a last-resort option, deployed only if combined surgery, SRL, and pegvisomant failed to achieve control.

What Biochemical Control Would Have Changed

The difference between treated and untreated acromegaly is not subtle. A 2008 meta-analysis of 16 studies involving over 6,000 patients found that achieving GH levels below 2.5 ng/mL and normal IGF-1 reduced the standardized mortality ratio to approximately 1.1, essentially normalizing life expectancy [4]. Patients who fail to achieve biochemical control face an SMR of 1.9 to 3.2.

Cardiac Reversibility

Acromegalic cardiomyopathy is partially reversible with biochemical control if caught early. A study in the Journal of Clinical Endocrinology & Metabolism found that 12 months of SRL therapy improved left ventricular mass index and diastolic function in acromegaly patients, though improvements were less pronounced in patients with longer disease duration or pre-existing heart failure [18]. For Andre, early intervention (in his 20s or 30s) could have significantly altered the cardiac trajectory. By his 40s, the degree of myocardial fibrosis was likely too advanced for full reversal.

Life Expectancy Estimate

This is speculative, but grounded in published survival data. If Andre had achieved biochemical control by age 30 through surgery and adjuvant pharmacotherapy, his cardiovascular risk would have been substantially reduced. Assuming moderate residual complications (arthropathy, managed insulin resistance, treated sleep apnea), a life expectancy into his 60s or 70s is clinically plausible. He died at 46.

The Alcohol Factor

No clinical analysis of Andre the Giant is complete without addressing his well-documented alcohol consumption. Fellow wrestlers and friends have reported that Andre consumed 100+ beers in a single sitting on multiple occasions. While some of these accounts are likely exaggerated, even conservative estimates place his intake at levels that would cause severe hepatotoxicity and cardiomyopathy in any patient, let alone one with GH-driven organ hypertrophy.

Alcohol-induced cardiomyopathy and acromegalic cardiomyopathy share overlapping pathology: both cause myocardial fibrosis and ventricular dilation. In combination, the damage compounds. Any modern treatment protocol would need to include structured alcohol cessation support, hepatology monitoring, and cardiac imaging at regular intervals.

"Acromegalic cardiomyopathy is a disease of myocardial remodeling. Add chronic heavy alcohol use, and you have two independent pathways driving the same end-organ failure," as the Endocrine Society's 2014 guideline commentary notes regarding comorbidity management in acromegaly [8].

What Clinicians Can Learn From This Case

Andre the Giant's case is taught informally in endocrinology training programs because it illustrates what happens when acromegaly runs its full natural course without intervention. The clinical teaching points are straightforward. Early diagnosis changes outcomes. Biochemical control reduces mortality. Cardiovascular surveillance must begin at diagnosis. And patient reluctance to undergo treatment, often driven by fear, stigma, or practical constraints, is a barrier that clinicians must address directly.

The Endocrine Society recommends lifelong monitoring of GH, IGF-1, pituitary MRI, cardiac function, glucose metabolism, and colonoscopy in all acromegaly patients, regardless of disease control status [8]. Andre received none of this.

"Patients with acromegaly require comprehensive, long-term follow-up even after biochemical remission is achieved, given the persistent risk of cardiovascular, metabolic, and neoplastic complications," according to the 2014 Endocrine Society Clinical Practice Guideline on acromegaly [8].

Semaglutide 2.4 mg, the GLP-1 receptor agonist approved for weight management, has not been studied specifically in acromegaly patients, but given the prevalence of obesity and insulin resistance in this population, it could represent a future adjunctive therapy for metabolic comorbidities. No trial data currently supports this use in acromegaly specifically.